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Abstract. Gemcitabine is indicated in combination with cispl-
atin as first-line therapy for solid tumours including non-small 
cell lung cancer (NSCLC), bladder cancer and mesothelioma. 
Gemcitabine is an analogue of pyrimidine cytosine and func-
tions as an anti-metabolite. Structurally, however, gemcitabine 
has similarities to 5-aza-2-deoxycytidine (decitabine/
Dacogen®), a DNA methyltransferase inhibitor (DNMTi). 
NSCLC, mesothelioma and prostate cancer cell lines were 
treated with decitabine and gemcitabine. Reactivation of 
epigenetically silenced genes was examined by RT-PCR/
qPCR. DNA methyltransferase activity in nuclear extracts 
and recombinant proteins was measured using a DNA methyl-
transferase assay, and alterations in DNA methylation status 
were examined using methylation-specific PCR (MS-PCR) 
and pyrosequencing. We observe a reactivation of several 
epigenetically silenced genes including GSTP1, IGFBP3 and 
RASSF1A. Gemcitabine functionally inhibited DNA methyl-
transferase activity in both nuclear extracts and recombinant 
proteins. Gemcitabine dramatically destabilised DNMT1 
protein. However, DNA CpG methylation was for the most 
part unaffected by gemcitabine. In conclusion, gemcitabine 
both inhibits and destabilises DNA methyltransferases and 
reactivates epigenetically silenced genes having activity 
equivalent to decitabine at concentrations significantly lower 
than those achieved in the treatment of patients with solid 
tumours. This property may contribute to the anticancer 
activity of gemcitabine.
Introduction
Gemcitabine is a well-established anticancer agent and has 
been FDA approved either as a single agent for the treatment 
of pancreatic cancer (1) or in combination with another 
agent (carboplatin, cisplatin or paclitaxel) for the treatment 
of ovarian (2) and metastatic breast cancer (3). Cisplatin is 
indicated as first-line therapy for inoperable, locally advanced 
(stage IIIA or IIIB) or metastatic (stage IV) non-small cell 
lung cancer (NSCLC) (4,5), and has also been studied in 
other solid tumours such as malignant pleural mesothelioma 
(MPM) (6,7) and prostate cancer (8,9).
Gemcitabine is considered to act as a pyrimidine-type 
anti-metabolite. The agent is a prodrug and requires intracel-
lular conversion to two active metabolites, gemcitabine 
diphosphate and gemcitabine triphosphate, which can func-
tion in two ways: by binding to and irreversibly inhibiting 
ribonucleotide reductase (RNR) and by replacing one of the 
building blocks of nucleic acids, in this case cytosine, during 
DNA replication (10).
Aberrant epigenetic regulation of gene expression is a 
frequent event in cancer (11). Several of the proteins which 
regulate histone post-translational modifications have now 
been shown to play a role in resistance to various cancer 
therapies including cisplatin (12), gefitinib (13), etoposide (14) 
and tamoxifen (15).
DNA CpG methylation is another epigenetic modifica-
tion that is linked to loss of gene expression in cancer (16). 
Inhibitors targeting DNA methyltransferases have been 
developed. Of these 5-azacytidine (Vidaza®) and 5-aza-
2-deoxycytidine (decitabine/Dacogen®) have gained FDA 
approval for the treatment of myelodysplastic syndrome 
subtypes (17,18).
Notably, the chemotherapy agent doxorubicin has been 
shown to inhibit the DNA methyltransferase DNMT1 (19) 
and indicates that other chemotherapy drugs may potentially 
inhibit the epigenetic enzymatic machinery. Since decitabine 
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and gemcitabine are cytosine analogues, and share similar 
structural features (Fig. 1), we reasoned that gemcitabine 
may also be able to act as a DNA methyltransferase inhibitor 
(DNMTi).
Materials and methods
Cell lines. The A549 (adenocarcinoma), SKMES1 (squamous 
cell carcinoma), H-28 (MPM), 22Rv1 (prostate), LNCaP 
(prostate) and Du145 (prostate) cell lines were purchased 
from the ATCC (LGC Promochem). Cells were cultured in 
appropriate media and maintained at 37˚C in a humidified 
atmosphere containing 5% CO2.
Cell line treatments. Decitabine was purchased from Merck 
and dissolved in methanol. Cell cultures were treated for 48 h 
at a final concentration of 5 µM, with the media and drug 
replaced every 24 h as previously described (20).
Gemcitabine was supplied by Eli Lilly and dissolved in 
phosphate-buffered saline (PBS) at a final concentration of 
38 mg/ml (120.14 mM). Cell cultures were treated for 48 h at 
final concentrations of 0.2, 0.5 or 1 µM with the media and 
drug replaced every 24 h. We chose to use this concentration 
based on literature searches in Pubmed.
RNA isolation and RT-PCR amplification. Total RNA was 
extracted using TRI Reagent® (MRCgene) according to the 
manufacturer's instructions. One microgram of total RNA 
was used to generate cDNA using M-MLV-reverse transcrip-
tase (Promega) according to the manufacturer's instructions.
Expression of VEGFR1, VEGFR2, sFRP4, RASSF1A 
and β-actin was examined by RT-PCR, using primers and 
PCR conditions outlined in Table I. Each PCR was carried 
out for 35 cycles. Ten microlitres of the experimental RT-PCR 
product and 2 µl of the β-actin RT-PCR product were loaded 
onto a 1% agarose gel.
Quantitative PCR. RNA was isolated from the cell lines 
using a miRVana miRNA isolation kit (Applied Biosystems, 
UK) according to the manufacturer's guidelines. Total RNA 
(1 µg) was reverse transcribed using the high capacity cDNA 
Archive kit. Expression of GSTP1 (TaqMan® gene expression 
assay ID: Hs00168310_m1) and IGFBP3 (TaqMan gene 
expression assay ID: Hs00181211_m1) was quantified in the 
cell lines by qRT-PCR. Human phosphoglycerate kinase 1 
(PGK1) was used as an endogenous control (TaqMan gene 
expression assay ID: Hs99999906_m1). TaqMan PCR reac-
tions were performed in triplicate on an ABI Prism 7900 
sequence detection system. Gene expression was calculated 
relative to the untreated cell lines, using SDS RQ Manager 1.2 
software, which automatically determines relative quantities 
(RQ), by applying the arithmetic formula 2-∆∆CT. All equip-
ment and reagents were supplied by Applied Biosystems, 
Foster City, CA.
DNA methyltransferase assay. Analysis of DNA methyltrans-
ferase activity was carried out using the EpiQuik™ DNA 
methyltransferase activity/inhibition assay kit (Epigentek) 
using both recombinant DNMTs (Epigentek) and nuclear 
extracts isolated with the EpiQuik Nuclear Extraction kit II 
(Epigentek) according to the manufacturer's instructions. 
Following consultation with the manufacturers, the recombi-
nant proteins were incubated with the various concentrations 
of decitabine or gemcitabine for 90 min at room temperature 
prior to conducting the methyltransferase assay.
Genomic DNA isolation, bisulfite conversion and MS-PCR 
analysis. Genomic DNA was isolated from the cell lines using 
a solution containing 0.5% SDS and 100 µg/ml Proteinase K 
(21).
Genomic DNA from the cell lines (500 ng) was bisul-
fite modified using the EpiTect Bisulfite kit (Qiagen, UK), 
following the manufacturer's guidelines. EpiTect methylated 
DNA and unmethylated DNA were used as controls.
Promoter hypermethylation of the GSTP1 promoter was 
analysed by methylation-specific PCR (MS-PCR) in the 
LNCaP and 22Rv1 cell lines using the GoTaq HotStart enzyme 
(Promega). PCR primer sets complementary to both modified, 
methylated DNA (M) and modified, unmethylated DNA (U) 
were designed for GSTP1: GSTP1 MF2, 5'-TTCGGGGGTGTA 
GCGGTCGTC-3'; GSTP1 MR1, 5'-CCAACGAAAACCTCGC 
GACCTCCG-3' (expected product, 145 bp); GSTP1 UF2, 
5'-GATGTTTGGGGTGTAGTGGTTGTT-3'; GSTP1 UR1, 5'- 
AAACTCCAACAAAAACCTCACAACCTCCA-3' (expected 
product, 154 bp).
Bisulfite pyrosequencing. Pyrosequencing methylation anal-
ysis (PMA) of the LINE-1.2 element, the RASSF1A promoter 
and the VEGFR gene promoters, was performed as previ-
ously described (22-24). Genomic DNA (500-1,000 ng) was 
bisulfite treated, using the EpiTect Bisulfite kit or the EZ DNA 
Methylation™ kit (ZymoResearch). The PyroMarkAssay 
Design software was used to design the primers for amplifica-
tion and sequencing to cover a number of CpG sites as shown 
in Table II. PCR amplification products were cleaned and 
subjected to pyrosequencing on either a PyroMark Q96 ID 
pyrosequencer using PyroMark Gold Q96 SQA reagents (all 
were from Qiagen), or on a Q24 pyrosequencer according to 
the manufacturer's protocol (Biotage). The methylation of C in 
each analysed CpG site was quantified from 0 to 100%, using 
the PyroMark software (Qiagen).
Western blot analysis. Protein lysates were extracted from cell 
cultures using RIPA buffer [50 mM Tris HCl, pH 7.4, 150 mM 
NaCl, 1 mM EDTA, 1% (v/v) Triton X-100, 0.1% (w/v) SDS], 
supplemented with 10 µl phenylmethylsulfonyl f luoride 
Figure 1. Chemical structures of (A) 5-aza-2-deoxycytidine (decitabine) and 
(B) gemcitabine.
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(87 mg/ml in 96% EtOH) and 100 µl protease inhibitor 
cocktail (2 mM AEBSF, 1 mM EDTA, 130 µM bestatin, 
14 µM E-64, 1 µM leupepin, 0.3 µM aprotinin). Lysates 
were separated by SDS/PAGE and subsequently transferred 
onto pre-activated polyvinylidene fluoride nitrocellulose 
membranes (PVDF). Membranes were blocked for 1 h at 
room temperature (RT) in TBST [10 mM Tris-HCl (pH 7.5), 
10 mM NaCl, 0.1% (v/v) Tween 20] containing 5% nonfat dry 
milk powder. Membranes were immunoblotted overnight at 
4˚C in TBST with 5% nonfat dry milk powder with DNMT1 
(supplier) with HDAC1 (Cell Signalling Technologies) used 
as a loading control as appropriate. All secondary antibodies 
were HRP-labelled and bound antibody complexes were 
detected using the Supersignal West Pico Chemiluminescent 
kit (Pierce, Rockford, IL, USA).
Results
Gemcitabine reactives mRNA expression of epigenetically 
silenced genes. A549 (NSCLC), H28 (MPM), LNCaP (pros-
tate) and 22Rv1 (prostate) cells were treated with either 
decitabine or gemcitabine and the effects of these drugs on 
gene expression were examined. In A549 cells decitabine and 
gemcitabine induced both VEGFR1 and VEGFR2 (Fig. 2A). 
In the H28 cell line a gene previously shown to be epige-
netically silenced in this cell line by DNA CpG methylation 
(25,26), sFRP4, was reactivated by both drugs (Fig. 2B). Both 
GSTP1 and IGFBP3 have been shown to be epigenetically 
silenced by DNA CpG methylation in prostate cancer by us 
and others (27-29). Using quantitative PCR we measured the 
effect of decitabine and gemcitabine on these genes in two 
prostate cancer cell lines (LNCaP and 22Rv1). Both drugs 
were shown to significantly induce expression of GSTP1 
(Fig. 2C) and IGFBP3 (Fig. 2D).
As all these genes were examined separately in different 
cell lines we reviewed the literature to find whether there 
was a common gene frequently silenced by DNA CpG 
methylation in lung, MPM and prostate cell lines. From this 
analysis we chose the gene RASSF1A which was shown to be 
silenced by methylation in several of our cell lines (30-32). 
Gemcitabine was able to reactivate/upregulate RASSF1A in 
3 out of the 4 cell lines tested whereas decitabine reactived 
RASSF1A in 4 out of the 4 cell lines at all concentrations 
tested (Fig. 3).
Decitabine functions in vitro and in vivo to inhibit DNA 
methyltransferases. A DNA methyltransferase activity/inhibi-
tion assay was used to measure the effects of gemcitabine on 
DNMT enzymatic activity, with decitabine used as a positive 
inhibitor control. Using recombinant DNMT protein mixture 
we demonstrated that both decitabine and gemcitabine inhib-
ited DNMT activity (Fig. 4A and B). Furthermore, DNMT 
activity was also inhibited in nuclear extracts from cells 
exposed to either decitabine or gemcitabine (Fig. 4C and D), 
indicating that gemcitabine inhibits DNA methyltransferase 
activity.
Gemcitabine affects DNMT1 protein stability. Decitabine 
has been shown to selectively degrade DNMT1 protein levels 
by a proteasomal-based pathway (33). To examine whether 
gemcitabine also affects the levels of DNMT1 protein, 
western blot analyses were carried out on extracts from 
Table I. Primers and annealing temperatures for RT-PCR.
Primer Set Sequence Annealing  Temp (˚C)/PCR cycles
VEGFR1 F: 5'-CAAGTGGCCAGAGGCATGGAGTT-3' 56˚C/35 cycles
 R:5'-GATGTAGTCTTTACCATCCTGTTG-3' 
VEGFR2 F: 5'-GAGGGCCTCTCATGGTGATTGT-3' 56˚C/35 cycles
 R: 5'-TGCCAGCAGTCCAGCATGGTCTG-3' 
sFRP4 F: 5'-TCTATGACCGTGGCGTGTGC-3' 56˚C/35 cycles
 R: 5'-ACCGATCGGGGCTTAGGCGTTTAC-3' 
RASSF1A F: 5'-CAGATTGCAAGTTCACCTGCCACTA-3' 56˚C/35 cycles
 R: 5'-GATGAAGCCTGTGTAAGAACCGTCCT 
β-actin F: 5'-TGTTTGAGACCTTCAACACCC-3' 56˚C/35 cycles
 R: 5'-AGCACTGTGTTGGCGTACAG-3' 
F, forward; R, reverse.
Table II. Primers for bisulfite pyrosequencing.
LINE1.2 (6 CpGs)
  LINE-1 fwd: 5'-BIO-TAGGGAGTGTTAGATAGT GG-3',
  LINE-1 rev: 5'-AACTCCCTAACCCCTTAC-3', 
  LINE-1 seq: 5'-CAAATAAAACAATACCTC-3'.
RASSF1A (9 CpGs)
  RASSF1 methF: 5'-AGTATAGTAAAGTTGGTTTTTAGAAA-3'
  RASSF1 methR: 5'-CCCTTCCTTCCCTCCTT-3'
  RASSF1 methPSEQ: 5'-AAGTTGGTTTTTAGAAATA-3'
VEGFR1 (15 CpGs)
  VEGFR1 PyroF: 5'-AGGAGGGGTAAGGGTAAGAG-3'
  VEGFR1 PyroR: 5'-TCCCCACCTACCCTCTTCTT-3'
  VEGFR1 PyroSEQ: 5'-GGGAGAGGAGTAAAGATTTTGAATT-3'
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cells treated with various concentrations of gemcitabine or 
decitabine. Gemcitabine was found to affect DNMT1 protein 
levels to different degrees for all the cell lines examined 
(Fig. 4E).
Figure 2. Reactivation of silenced genes by gemcitabine in cancer cell lines. A549 (NSCLC), H28 (MPM), 22Rv1 and LNCaP cells were treated with either 
decitabine (final concentration 5 µM) or gemcitabine (final concentration 1 µM) for 48 h with the media and drugs being replaced every 24 h. Reactivation of 
gene expression in the cell lines was monitored using either RT-PCR or qPCR. Results are provided for (A) VEGFR1 and VEGFR2 in A549 cells, (B) sFRP4 
in H28 cells, (C) GSTP1 (p<0.05) and (D) IGFBP3 (P<0.05). The results clearly demonstrated that these genes were reactivated in response to treatment with 
either drug. Statistical significance was determined using the non-parametric Kruskal-Wallis test. 
Figure 3. Reactivation of a commonly silenced gene by gemcitabine in a panel of cancer cell lines. RASSF1A was identified by literature searches as being 
commonly silenced by DNA CpG methylation in 4 out of the 5 cell lines as indicated. Cells (A549, SKMES1, Du145 and 22Rv1) were treated with either 
decitabine or gemcitabine at the concentrations indicated, and expression of RASSF1A was examined by RT-PCR. Reactivation/upregulation of RASSF1A 
was observed to occur in 4 out of the 4 cell lines following decitabine treatment and in 3 out of the 4 cell lines following gemcitabine treatment. 
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Gemcitabine does not alter global DNA CpG methylation 
or at the promoters of reactivated genes. Schafer and 
colleagues published data demonstrating that gemcitabine 
affects DNA methylation in cancer cells by inhibiting 
nucleotide excision repair (NER)-mediated DNA demeth-
ylation. Intriguingly, the authors showed that gemcitabine 
treatments did not affect global levels of DNA methylation 
but induced hypermethylation and silencing of MLH1 (34).
Using pyrosequencing of long interspersed nucleotide 
element (LINE-1) sequences, we examined global methylation 
in our cell lines. In agreement with Schafer et al (34), we did 
not observe any gross alterations in the global DNA CpG 
methylation following treatment with gemcitabine (Table III). 
For the lower concentration of decitabine tested (0.2 µM) we 
noted a decrease in CpG methylation which did not occur in 
the cells treated at the higher concentration (1 µM) in agree-
ment with effects reported by others (35).
Next, we examined the effect of decitabine and 
gemcitabine on CpG methylation within RASSF1A. Again 
decitabine caused alterations to DNA CpG methylation levels 
at the lower concentration, yet there was no effect on methyla-
tion at the higher concentration (Table III). For the most part 
gemcitabine did not alter DNA CpG methylation for either 
concentration examined (Table III). Similar results were 
observed for VEGFR1 (data not shown).
GSTP1 has been previously shown to be downregulated 
by DNA CpG methylation (27-29). Given that we were able to 
demonstrate that both gemcitabine and decitabine reactivated 
the expression of GSTP1 in prostate cancer cell lines (Fig. 2), 
using MS-PCR, we examined whether or not there is a loss 
of methylation at the GSTP1 promoter in the 22Rv1 cell line. 
Our results showed a clear increase in the levels of unmethyl-
ated DNA at the GSTP1 promoter following treatment with 
either drug, indicating that there may be some changes 
to DNA CpG methylation occurring in cells treated with 
gemcitabine (Fig. 5).
Discussion
Gemcitabine is a well-established chemotherapy agent used as 
a single-agent treatment in pancreatic cancer, or in combina-
tion with various other agents in the treatment of many solid 
tumours. Its mode of action is generally considered to be that of 
an anti-metabolite acting to either inhibit ribonucleotide reduc-
tase (RNR) or by replacing cytidine during DNA replication.
Aberrant epigenetic regulation through DNA CpG meth-
ylation is a frequent event in cancer and reactivation of the 
target of methylation induced silencing 1 (TMS1) by DNA 
methyltransferase inhibitors (DNMTi) was found to enhance 
sensitivity to gemcitabine in pancreatic cancer cells (36).
Figure 4. Gemcitabine directly inhibits DNA methyltransferase activity and affects DNMT1 protein levels. Both (A) decitabine and (B) gemcitabine inhibited 
DNMT activity in recombinant proteins incubated with either drug. DNA methyltransferase activity was measured using EpiQuik DNA methyltransferase 
activity/inhibition assay kit and % inhibition was noted relative to untreated controls. Significance was determined using one-way analysis of variance (ANOVA). 
Following ANOVA a post hoc test was performed using the Dunnett's multiple comparisons test. Differences were considered significant at P<0.05. Cells 
were treated with decitabine or gemcitabine, nuclear extracts were prepared and % DNA methyltransferase inhibition was measured. Results are presented 
for (C) SK-MES-1 and (D) H28 cells (n=2 independent experiments). The results showed that overall DNA methyltransferase activity was inhibited by either 
drug. Similar results were obtained for A549 (data not shown). (E) Western blot analyses were performed on nuclear extracts of cells treated with decitabine or 
gemcitabine for DNMT1. HDAC1 was used as a loading control. Gemcitabine and decitabine were shown to affect the levels of DNMT1 to various degrees in the 
cell lines tested.
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We noted that gemcitabine shares structural similarity 
with the FDA-approved DNMTi decitabine (Dacogen) 
(Fig. 1) and tested whether or not it has the ability to affect 
DNA CpG methylation. We showed that gemcitabine 
actively induces expression of epigenetically silenced genes 
in lung, mesothelioma (MPM) and prostate cancer cell 
lines (Figs. 2 and 3). We showed that gemcitabine directly 
inhibits DNA methyltransferases (Fig. 4). In addition, we also 
showed that gemcitabine depletes levels of DNMT1 similar 
to decitabine (Fig. 4). However, despite gemcitabine's ability 
to inhibit DNMTs, alter cellular DNMT1 protein levels and 
reactivate epigenetically silenced genes, there were few if 
any changes to DNA CpG methylation levels. We provide 
some evidence that active demethylation of an epigenetically 
silenced gene can occur (Fig. 5), but another mechanism may 
have to be invoked.
Schafer et al (34) published additional data demonstrating 
that gemcitabine affects DNA methylation in cancer cells 
by inhibiting nucleotide excision repair (NER)-mediated 
DNA demethylation. The authors showed that gemcitabine 
treatments did not affect global levels of DNA methylation 
but induced hypermethylation and silencing of MLH1 (34). In 
agreement with the authors we also found that global levels 
of DNA CpG methylation were unaffected. In addition, meth-
ylation at the promoters of genes which could be reactivated 
following treatments with either decitabine or gemcitabine did 
not demonstrate any major changes in methylation status. This 
may in part be due to the concentrations of drugs used. For 
example, it has been established that high concentrations of 
decitabine have less effect on DNA methylation due to cyto-
static effects, and our results using pyrosequencing confirm 
this demonstrating that changes in DNA methylation only 
occurred at the lower concentration of drug used (Table III). 
Using MTT assays we examined cellular proliferation 
across a range of concentrations (decitabine 200-5,000 nM; 
gemcitabine 50-1,000 nM) in A549 and SKMES1 cells. 
While decitabine did not affect cellular proliferation to any 
appreciable effect at any concentration, gemcitabine caused 
significant decreases (of the order 25-50%) in cellular prolif-
eration (data not shown), which was not unexpected given the 
other known mechanisms of action of this drug.
Schafer et al (34) used a range of concentrations (34, 
67 or 134 nM), whereas we used higher concentrations 
(0.2-1 µM). It must be noted, however, that in gemcitabine 
infusion studies of patients with solid tumours, blood concen-
trations of gemcitabine at Day 1 of infusion varied between 
18 and 77 µM and at Day 15 between 13 and 90 µM (37). As 
such the amount of gemcitabine used in our analysis was still 
below the levels utilised in patients.
The concentration of gemcitabine may become a critical 
determinant in how this chemotherapeutic agent is used in the 
clinic. For instance, in a study using MPM cells, gemcitabine 
inhibited the secretion of the proinflammatory cytokine IL-6 
at drug concentrations that produced only small decreases in 
cell viability, whereas at higher doses a surge of IL-6 release 
was noted (38). We also observed an increase in the pro-
tumourigenic cytokine IL-23 in a NSCLC cell line treated 
with gemcitabine (Gray and O'Byrne, unpublished data).
How then does gemcitabine induce or reactivate epigeneti-
cally silenced genes. The nitrogen substitution of carbon 5 in 
the cytosine ring (Fig. 1) is involved in the mechanism 
of DNMT inactivation. As this nitrogen is not present in 
gemcitabine it may be that some sort of steric hindrance is 
involved affecting DNMTs and or methyl-binding proteins. 
Conceivably by inhibiting binding of methyl-binding protein 
complexes to DNA CpG sites this may relax chromatin and 
result in the re-expression of silenced genes.
Table III. Percentage of methylation for LINE-1 and RASSF1A 
as determined by pyrosequencing.
Cell line Treatment LINE-1 RASSF1
A549 UT 55.8 85.2
 DAC 0.2 32.8 45.3
 DAC 1.0 51.3 79.2
 Gem 0.2 54.7 85.8
 Gem 1.0 55.7 86.2
SKMES-1 UT 53.1   7.3
 DAC 0.2 45.2   4.4
 DAC 1.0 52.7   6.5
 Gem 0.2 51.2   5.2
H28 UT 68.0 94.9
 DAC 0.2 47.8 65.8
 DAC 1.0 63.8 88.1
 Gem 0.2 69.6 94.6
 Gem 1.0 68.2 94.5
Du145 UT 65.2 71.2
 DAC 0.2 45.8 51.0
 DAC 1.0 56.5 64.0
 Gem 0.2 64.3 71.6
 Gem 1.0 66.0 71.9
22Rv1 UT 50.0 83.8
 DAC 0.2 37.7 53.3
 DAC 1.0 42.5 61.2
 Gem 0.2 50.4 82.6
 Gem 1.0 52.0 74.3
UT, untreated; DAC 0.2, decitabine 0.2 µM; DAC 1.0, decitabine 
1.0 µM; Gem 0.2, gemcitabine 0.2 µM; Gem 1.0, gemcitabine 
1.0 µM.
Figure 5. Gemcitabine affects DNA CpG methylation directly at the 
promoters of silenced genes. MS-PCR analysis of a known hypermethylated 
region of the GSTP1 promoter was carried out on bisulfite-modified DNA 
extracted from 22Rv1 cells treated as described. The results showed that in 
untreated cells the region was predominantly methylated (M). Following 
treatment there was a clear increase in the amount of unmethylated (U) PCR 
product in the cells treated with either drug. UT, untreated; DAC, decitabine; 
GEM, gemcitabine.
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The results presented by us and Schafer et al (34) demon-
strate a novel indication for gemcitabine and may have 
important implications in oncology as DNA methylation 
effects are potentially useful as biomarkers to either monitor 
response to therapy (39), or may have predictive value 
(40). In particular, the ability of gemcitabine to reactivate 
epigenetically silenced genes indicates a potential means to 
monitor and identify those patients who actually respond to 
gemcitabine treatment.
There are exciting new avenues which could be exploited, 
for example the use of low dose gemcitabine regimens 
combined with other epigenetic targeting drugs such histone 
deacetylase inhibitors. In addition low dose regimens may 
have the ability to sensitise resistant cancer to other cancer 
therapies. Further study will be required to fully delineate 
these possibilities.
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